Lyra Therapeutics : Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
New data presented includes: - First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) - - LYR-210 (7500µg) decreased ethmoid opacification at week 24, a measure of disease modification - - LYR-210 (7500µg) reduced the need for rescue medication - - Separately, Lyra also reported an analysis showing that LYR-210 (7500µg) achieved statistically significant improvement across 3 cardinal symptoms at week 24 in the LANTERN study ...
Source: marketscreener.com